[go: up one dir, main page]

CR20110463A - Compuesto de anillo fusionado y su uso - Google Patents

Compuesto de anillo fusionado y su uso

Info

Publication number
CR20110463A
CR20110463A CR20110463A CR20110463A CR20110463A CR 20110463 A CR20110463 A CR 20110463A CR 20110463 A CR20110463 A CR 20110463A CR 20110463 A CR20110463 A CR 20110463A CR 20110463 A CR20110463 A CR 20110463A
Authority
CR
Costa Rica
Prior art keywords
fusioned
ring compound
symbol
salts
receptor antagonist
Prior art date
Application number
CR20110463A
Other languages
English (en)
Inventor
Tsuyoshi Maekawa
Hideyuki Igawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR20110463A publication Critical patent/CR20110463A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se provee un nuevo compuesto, en donde cada símbolo es como se definió en la memoria descriptiva o una de sus sales, que tiene una actividad antagonista del receptor de angiotensina.
CR20110463A 2009-01-30 2011-08-26 Compuesto de anillo fusionado y su uso CR20110463A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009020720 2009-01-30

Publications (1)

Publication Number Publication Date
CR20110463A true CR20110463A (es) 2011-12-01

Family

ID=42026435

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110463A CR20110463A (es) 2009-01-30 2011-08-26 Compuesto de anillo fusionado y su uso

Country Status (37)

Country Link
US (4) US8283353B2 (es)
EP (1) EP2384327B1 (es)
JP (2) JP4892649B1 (es)
KR (1) KR20110113758A (es)
CN (2) CN102369205B (es)
AR (1) AR075344A1 (es)
AU (1) AU2010208863A1 (es)
CA (1) CA2750710C (es)
CL (1) CL2011001848A1 (es)
CO (1) CO6362011A2 (es)
CR (1) CR20110463A (es)
CY (1) CY1114530T1 (es)
DK (1) DK2384327T3 (es)
DO (1) DOP2011000249A (es)
EA (1) EA019823B1 (es)
EC (1) ECSP11011294A (es)
ES (1) ES2433225T3 (es)
GE (1) GEP20135961B (es)
HK (1) HK1162505A1 (es)
HR (1) HRP20131017T1 (es)
IL (1) IL214283A0 (es)
MA (1) MA33071B1 (es)
ME (1) ME01621B (es)
MX (1) MX2011008058A (es)
MY (1) MY152946A (es)
NZ (1) NZ594606A (es)
PE (1) PE20120593A1 (es)
PL (1) PL2384327T3 (es)
PT (1) PT2384327E (es)
RS (1) RS53012B (es)
SG (1) SG173135A1 (es)
SI (1) SI2384327T1 (es)
TN (1) TN2011000368A1 (es)
TW (2) TWI468410B (es)
UY (1) UY32409A (es)
WO (1) WO2010087515A1 (es)
ZA (1) ZA201105867B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI468410B (zh) * 2009-01-30 2015-01-11 Takeda Pharmaceutical 稠環化合物及其用途
EP2655375B1 (fr) 2010-12-23 2014-12-03 Sanofi Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
CZ304252B6 (cs) * 2011-04-11 2014-01-29 Zentiva, K. S. Způsob výroby 2-ethoxy-1-((2´-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)bifenyl-4-yl)methyl)-1H-benzo[d]imidazol-7-karboxylátů a jejich převedení na azilsartan
KR102519922B1 (ko) 2016-06-20 2023-04-11 노파르티스 아게 트리아졸로피리미딘 화합물의 결정질 형태
US11937602B2 (en) 2017-09-26 2024-03-26 Ecolab Usa Inc. Solid acid/anionic antimicrobial and virucidal compositions and uses thereof
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
CN116348458A (zh) 2019-08-14 2023-06-27 因赛特公司 作为cdk2抑制剂的咪唑基嘧啶基胺化合物
PH12022550884A1 (en) 2019-10-11 2023-05-03 Incyte Corp Bicyclic amines as cdk2 inhibitors
CN112745319B (zh) * 2019-10-30 2022-06-17 中国科学院上海药物研究所 一类取代三环结构的化合物、其制备方法及用途
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672892B1 (fr) * 1991-02-20 1994-01-14 Synthelabo Derives de 4-pyrimidinones, leur preparation et leur application en therapeutique.
US5472967A (en) 1991-02-20 1995-12-05 Synthelabo 4-pyrimidinone derivatives their preparation and their application in therapy
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
TW251288B (es) * 1991-06-27 1995-07-11 Takeda Dharm Industry Co Ltd
IT1250749B (it) * 1991-08-02 1995-04-21 Luso Farmaco Inst Composti eterociclici ad attivita' a ii antagonista
FR2687677B1 (fr) * 1992-02-24 1996-10-11 Union Pharma Scient Appl Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
US5389632A (en) 1992-02-24 1995-02-14 Laboratoires Upsa Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists
US5387747A (en) 1992-02-24 1995-02-07 Laboratoires Upsa Triazolopyrimidine derivatives which are angiotensin II receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present
IT1263804B (it) 1993-01-22 1996-09-03 Luso Farmaco Inst Derivati pirimidinonici fusi con eterocicli azotati ad attivita' a ii antagonista
GB9406573D0 (en) 1994-03-31 1994-05-25 Merck Sharp & Dohme Medicaments
AU5982296A (en) 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination of an angi otensin ii antagonist and spironolactone
AU6039296A (en) 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist
CA2224222A1 (en) 1995-06-07 1996-12-19 G.D. Searle & Co. Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure
PL185150B1 (pl) 1995-06-07 2003-03-31 Searle & Co Kompozycja farmaceutyczna do leczenia zaburzeń sercowo-naczyniowych
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
SE0101579D0 (sv) 2001-05-04 2001-05-04 Astrazeneca Ab New compounds
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
TW200418835A (en) 2003-01-24 2004-10-01 Tanabe Seiyaku Co A pyrazolopyrimidine compound and a process for preparing the same
US20050065184A1 (en) 2003-08-29 2005-03-24 Aaipharma Inc. Method of reducing the risk of oxidative stress
CA2553724A1 (en) * 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
NZ551938A (en) 2004-06-02 2010-07-30 Takeda Pharmaceutical Fused heterocyclic compound
AU2005256634B2 (en) 2004-06-23 2010-12-09 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1-receptor antagonists
US20050288272A1 (en) 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
CA2616150A1 (en) 2005-07-27 2007-02-01 Talia Weinstein Inhibition of the renin-angiotensin system for the treatment of renal, vascular and cartilage pathology
WO2007053406A1 (en) 2005-10-28 2007-05-10 Novartis Ag Combinations of antihypertensive and cholesterol lowering agents
WO2007051007A2 (en) 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
US20080064871A1 (en) 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
WO2008060899A2 (en) 2006-11-09 2008-05-22 Ore Pharmaceuticals Inc. Breast cancer screening and treatment methods
US20090012052A1 (en) * 2006-11-09 2009-01-08 Ore Pharmaceuticals Inc. Method for treating er+ breast cancer
CA2670404A1 (en) * 2006-11-24 2008-05-29 Takeda Pharmaceutical Company Limited Heteromonocyclic compound and use thereof
WO2008143262A1 (ja) 2007-05-21 2008-11-27 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
CA2703019A1 (en) 2007-09-20 2009-03-26 University Of Rochester Method and compositions for treatment or prevention of inflammatory conditions
BRPI0908603A2 (pt) 2008-03-24 2020-08-18 Novartis Ag inibidores de metaloprotease de matriz com base em arilsulfonamida.
EP2279009A4 (en) 2008-05-05 2011-09-21 Univ Rochester METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PATHOLOGICAL CARDIAC REMODELING AND CARDIAC INSUFFICIENCY
TWI468410B (zh) * 2009-01-30 2015-01-11 Takeda Pharmaceutical 稠環化合物及其用途

Also Published As

Publication number Publication date
WO2010087515A1 (en) 2010-08-05
HK1162505A1 (en) 2012-08-31
DK2384327T3 (da) 2013-10-28
CN103788097A (zh) 2014-05-14
TW201031669A (en) 2010-09-01
JP2011251970A (ja) 2011-12-15
CO6362011A2 (es) 2012-01-20
EP2384327A1 (en) 2011-11-09
CA2750710C (en) 2018-09-04
NZ594606A (en) 2013-06-28
US8592431B2 (en) 2013-11-26
EA201101138A1 (ru) 2012-04-30
AU2010208863A1 (en) 2011-09-08
ECSP11011294A (es) 2011-09-30
JP4892649B1 (ja) 2012-03-07
CN102369205A (zh) 2012-03-07
CY1114530T1 (el) 2017-01-25
JP5676379B2 (ja) 2015-02-25
PT2384327E (pt) 2013-11-07
IL214283A0 (en) 2011-09-27
ZA201105867B (en) 2012-10-31
ES2433225T3 (es) 2013-12-10
EP2384327B1 (en) 2013-07-31
US9115136B2 (en) 2015-08-25
AR075344A1 (es) 2011-03-23
HRP20131017T1 (hr) 2013-12-06
TWI468410B (zh) 2015-01-11
ME01621B (me) 2014-09-20
DOP2011000249A (es) 2011-09-15
KR20110113758A (ko) 2011-10-18
US8921379B2 (en) 2014-12-30
CA2750710A1 (en) 2010-08-05
US8283353B2 (en) 2012-10-09
PL2384327T3 (pl) 2013-12-31
CN103788097B (zh) 2016-03-30
UY32409A (es) 2010-08-31
TN2011000368A1 (en) 2013-03-27
SG173135A1 (en) 2011-08-29
PE20120593A1 (es) 2012-05-21
MY152946A (en) 2014-12-15
EA019823B1 (ru) 2014-06-30
US20100197683A1 (en) 2010-08-05
US20110288087A1 (en) 2011-11-24
MX2011008058A (es) 2011-09-01
US20140046056A1 (en) 2014-02-13
TW201444848A (zh) 2014-12-01
CN102369205B (zh) 2014-10-29
SI2384327T1 (sl) 2013-12-31
JP2012513952A (ja) 2012-06-21
CL2011001848A1 (es) 2012-02-03
MA33071B1 (fr) 2012-02-01
GEP20135961B (en) 2013-11-11
US20110294832A1 (en) 2011-12-01
RS53012B (en) 2014-04-30

Similar Documents

Publication Publication Date Title
CR20110463A (es) Compuesto de anillo fusionado y su uso
ECSP12012011A (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo
ECSP13013022A (es) Agonistas de fgfr1 y sus métodos de uso
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
BR112015008251A2 (pt) pirrolobenzodiazepinas e conjugados destas
BRPI1008060A2 (pt) Agonistas e antagonistas do receptor s1p5, e métodos de uso do mesmo.
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
MX372661B (es) Anticuerpos anti-htra1 y metodos de uso.
HN2013000125S1 (es) Diseño de botella de marinero
CR20120362A (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo
CO6491037A2 (es) Derivados de pirazinooxazepina
BR112014024023A2 (pt) anticorpos idiotípicos anti-hcmv e usos dos mesmos
CL2009001363S1 (es) Pieza para maquina de afeitar.
UY34590A (es) Fenilimidazopirazoles sustituidos y su uso
ES2572368T3 (es) Tratamiento de la artrosis
CL2009001973S1 (es) Mostrador.
CL2008001296A1 (es) Uso de un antagonista del receptor y5 del npy para el tratamiento de un trastorno relacionado con el hipercortisolismo en un sujeto tal como el estres.
CL2012001192S1 (es) Botella.
RS53014B (en) 4R, 5S-ENANTIOMER 2- (5-METHYL-2-OXO-4-PHENYL-PYROLIDIN-1-IL) -ACETAMIDE WITH NOOTROPIC ACTIVITY
BRPI0906670A2 (pt) Catalisador, uso de um catalisador, e, processo de fischer-tropsch.
FR2980725B1 (fr) Dispositif de percage, ensembles correspondants et utilisation correspondante
BRPI1008099A2 (pt) bomba provida de um sistema, dispositivo de produção de eletricidade, e, utilização de uma bomba.
BRPI1007505A2 (pt) derivado de tetraidronaftaleno-2-ol, e, uso do mesmo.
CL2011000970S1 (es) Cepillo de dientes.
CL2009000054S1 (es) Frasco para cosmeticos.